3-ethoxy-2,2-dimethyl-propionic acid | 125181-31-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-ethoxy-2,2-dimethyl-propionic acid
• 英文别名: Aethoxy-pivalinsaeure；3-Aethoxy-2,2-dimethyl-propionsaeure；3-ethoxy-2,2-dimethylpropanoic acid
• CAS: 125181-31-9
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: NCRPBEZFYSLGGS-UHFFFAOYSA-N

物化性质

• 沸点：
  110-116 °C(Press: 10 Torr)
• 密度：
  1.007±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-ethoxy-2,2-dimethyl-propionic acid 生成 β-Aethoxypivalinsaeureaethylester
  参考文献：
  名称：

  Marcilly, Bulletin de la Societe Chimique de France, 1904, vol. <3>31, p. 129

  摘要：

  DOI：
• 作为产物：
  描述：

  β-Aethoxypivalinsaeureaethylester 以68%的产率得到
  参考文献：
  名称：

  ADAM, FRIEDHELM;BLUMBACH, JURGEN;DURCKHEIMER, WALTER;FISCHER, GERD;MENCKE+

  摘要：

  DOI：

文献信息

• Amelioration of the development of cataracts and other ophthalmic diseases
  申请人：——

  公开号：US20040002461A1

  公开（公告）日：2004-01-01

  Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: 1 where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  用于阻止白内障或黄斑变性发展的眼科可接受的组合物，包括药学上可接受的载体或稀释剂和具有以下公式的化合物：1其中R1和R2独立地为H或C1到C3烷基；R3和R4独立地为C1到C3烷基；且其中R1和R2一起取代，或R3和R4一起取代，或两者都可能是环烷基；R5为H，OH或C1到C6烷基；R6为C1到C6烷基，烯基，炔基或取代的烷基或烯基；R7为C1到C6烷基，烯基，炔基或取代的烷基或烯基；或者其中R6和R7，或R5，R6和R7一起形成具有3到7个原子的环烷基或杂环烷基。
• Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases
  申请人：Matier William L.

  公开号：US20130131052A1

  公开（公告）日：2013-05-23

  Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  眼科可接受的组合物，用于阻止白内障或黄斑变性的发展，包括一种药学可接受的载体或稀释剂和一种具有以下化学式的化合物：其中R1和R2分别为H或C1到C3烷基；R3和R4分别为C1到C3烷基；且其中R1和R2，一起取或R3和R4，一起取或两者都可以是环烷基；R5为H，OH或C1到C6烷基；R6为C1到C6烷基，烯基，炔基或取代的烷基或烯基；R7为C1到C6烷基，烯基，炔基或取代的烷基或烯基，或者其中R6和R7，或R5，R6和R7一起形成具有3到7个原子的碳环或杂环。
• [EN] ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF<br/>[FR] DÉRIVÉS D'ESTER DE N4-HYDROXYCYTIDINE ET LEUR UTILISATION
  申请人：SUZHOU SPRING SEA BIO PHARMACEUTICALS CO LTD

  公开号：WO2023083295A1

  公开（公告）日：2023-05-19

  The present disclosure relates to ester derivatives of N4-hydroxycytidine (NHC), to pharmaceutical compositions comprising thereof, to the preparation method thereof, and to the use and method of the ester derivatives of N4-hydroxycytidine to treat viral infections.

  本公开涉及N4-羟基胞嘧啶（NHC）的酯衍生物，其中包括制药组合物，其制备方法以及使用N4-羟基胞嘧啶的酯衍生物的方法来治疗病毒感染。
• ORGANIC SEMICONDUCTOR THIN FILM, ORGANIC SEMICONDUCTOR DEVICE, ORGANIC THIN FILM TRANSISTOR, AND ORGANIC ELECTRO-LUMINESCENCE ELEMENT
  申请人：KONICA MINOLTA HOLDINGS, INC.

  公开号：EP1758172A1

  公开（公告）日：2007-02-28

  An organic semiconductor thin film, comprising an organic semiconductor compound, wherein the organic semiconductor thin film is manufactured by a process of forming a film by using a solution or a dispersion at room temperature prepared by mixing the organic semiconductor compound and an organic solvent, and the half width of a diffraction peak having the maximum intensity is 0.4° or less in an X-ray diffraction spectrum of the film.

  一种由有机半导体化合物组成的有机半导体薄膜，其中有机半导体薄膜是通过使用有机半导体化合物和有机溶剂在室温下混合制备的溶液或分散液形成薄膜的工艺制造的，在薄膜的 X 射线衍射谱中，具有最大强度的衍射峰的半宽度为 0.4°或更小。
• [EN] AMELIORATION OF CATARACTS, MACULAR DEGENERATION AND OTHER OPHTHALMIC DISEASES<br/>[FR] AMELIORATION DE LA CATARACTE, DE LA DEGENERESCENCE MACULAIRE ET AUTRES MALADIES OPHTALMIQUES
  申请人：OTHERA PHARMACEUTICALS INC

  公开号：WO2005055926A3

  公开（公告）日：2006-12-07